SLC5A2 and cancer: For example, potential residual confounding that may partially explain the observed reduced risk of death associated with SGLT-2 inhibitors use might include other comorbidities (such as cancer, chronic lung and liver disease, and dementia), patient socio-economic status, physician characteristics, and regional characteristics.